117 related articles for article (PubMed ID: 38760263)
1. Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China.
Wang L; Liu L; Zhang Z; Li F; Ruan Y; He Y; Huang J; Zheng X
Clin Breast Cancer; 2024 Apr; ():. PubMed ID: 38760263
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.
Wu Y; Hu S; Liu X; Chen Y; Luan J; Wang S
Cost Eff Resour Alloc; 2024 Apr; 22(1):32. PubMed ID: 38659013
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
Xie J; Li S; Li Y; Li J
BMC Health Serv Res; 2023 Jun; 23(1):706. PubMed ID: 37386633
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US.
Chen J; Han M; Liu A; Shi B
Front Oncol; 2021; 11():734594. PubMed ID: 34778047
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
Lang Y; Chai Q; Tao W; Liao Y; Liu X; Wu B
Breast; 2023 Apr; 68():173-180. PubMed ID: 36780838
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
Cher BP; Goh S; Aziz MIA; Wong G; Ng Chee Hui R; Ong BS; Ng KH
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):217-225. PubMed ID: 38149409
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Shi D; Li Y; Liang X; Chen L
Front Oncol; 2023; 13():1162360. PubMed ID: 37251935
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.
Reinisch M; Bruzas S; Spoenlein J; Shenoy S; Traut A; Harrach H; Chiari O; Cremer E; Ataseven B; Gubelt L; Kuemmel S
Ther Adv Med Oncol; 2023; 15():17588359231200454. PubMed ID: 37789989
[TBL] [Abstract][Full Text] [Related]
10. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
[TBL] [Abstract][Full Text] [Related]
11. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
[TBL] [Abstract][Full Text] [Related]
13. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
[TBL] [Abstract][Full Text] [Related]
14. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Gómez Pardo P; Jhaveri KL; Delaney R; Valdez T; Wang H; Motwani M; Yoon OK; Verret W; Tolaney SM
Lancet; 2023 Oct; 402(10411):1423-1433. PubMed ID: 37633306
[TBL] [Abstract][Full Text] [Related]
15. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
[TBL] [Abstract][Full Text] [Related]
16. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38186268
[TBL] [Abstract][Full Text] [Related]
19. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Schreiber AR; Andress M; Diamond JR
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
[No Abstract] [Full Text] [Related]
20. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
Baek G; Jung L; Duong A; Gralow J
J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
